🧭Clinical Trial Compass

A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets… (NCT07497854) | Clinical Trial Compass

Not Yet RecruitingNot Applicable

A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea

3,000 participantsStarted 2026-10-01

Plain-language summary

The purpose of this study is to evaluate safety and effectiveness of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine during the PMS period as required by the Korean ministry of food and drug safety (MFDS).

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Subjects aged 19 years or older
✓. Subjects who administered NURTEC® ODT 75 mg (Rimegepant sulfate) according to the approved label
✓. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

What they're measuring

1

To evaluate the safety of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine.

Timeframe: 28 days after from last administration of NURTEC® ODT 75 mg (Rimegepant sulfate)

2

To evaluate the safety of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine.

Timeframe: 28 days after from last administration of NURTEC® ODT 75 mg (Rimegepant sulfate)

3

To evaluate the safety of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine.

Timeframe: 28 days after from last administration of NURTEC® ODT 75 mg (Rimegepant sulfate)

4

To evaluate the safety of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine.

Timeframe: 28 days after from last administration of NURTEC® ODT 75 mg (Rimegepant sulfate)

5

To evaluate the safety of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine.

Timeframe: 28 days after from last administration of NURTEC® ODT 75 mg (Rimegepant sulfate)

6

Trial details

NCT IDNCT07497854

SponsorPfizer

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2030-07-31

Contact for this trial

Pfizer CT.gov Call Center

1-800-718-1021 ClinicalTrials.gov_Inquiries@pfizer.com

View on ClinicalTrials.gov More Migraine With or Without Aura trials